KR102470319B1 - 항균성 화합물 - Google Patents

항균성 화합물 Download PDF

Info

Publication number
KR102470319B1
KR102470319B1 KR1020207015574A KR20207015574A KR102470319B1 KR 102470319 B1 KR102470319 B1 KR 102470319B1 KR 1020207015574 A KR1020207015574 A KR 1020207015574A KR 20207015574 A KR20207015574 A KR 20207015574A KR 102470319 B1 KR102470319 B1 KR 102470319B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
phenyl
cycloalkyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207015574A
Other languages
English (en)
Korean (ko)
Other versions
KR20200084875A (ko
Inventor
파울 메오
모하메드 나와즈 칸
세드릭 샤리에르
Original Assignee
디스쿠바 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102470319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 디스쿠바 엘티디. filed Critical 디스쿠바 엘티디.
Publication of KR20200084875A publication Critical patent/KR20200084875A/ko
Application granted granted Critical
Publication of KR102470319B1 publication Critical patent/KR102470319B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Warehouses Or Storage Devices (AREA)
KR1020207015574A 2017-11-03 2018-11-02 항균성 화합물 Active KR102470319B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718285.8 2017-11-03
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (2)

Publication Number Publication Date
KR20200084875A KR20200084875A (ko) 2020-07-13
KR102470319B1 true KR102470319B1 (ko) 2022-11-25

Family

ID=60664899

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015574A Active KR102470319B1 (ko) 2017-11-03 2018-11-02 항균성 화합물

Country Status (23)

Country Link
US (2) US11345694B2 (enExample)
EP (2) EP3704105B9 (enExample)
JP (2) JP7348897B2 (enExample)
KR (1) KR102470319B1 (enExample)
CN (1) CN111566099B (enExample)
AU (1) AU2018361828B2 (enExample)
BR (1) BR112020008531A2 (enExample)
CA (1) CA3081423A1 (enExample)
CL (2) CL2020001147A1 (enExample)
CO (1) CO2020005420A2 (enExample)
EA (1) EA202091118A1 (enExample)
ES (1) ES3005164T3 (enExample)
GB (1) GB201718285D0 (enExample)
GE (1) GEP20237522B (enExample)
IL (1) IL274229B2 (enExample)
MA (1) MA50504A (enExample)
MX (2) MX2020004562A (enExample)
NZ (1) NZ764310A (enExample)
PE (2) PE20211390A1 (enExample)
SG (1) SG11202003717UA (enExample)
UA (1) UA128475C2 (enExample)
WO (1) WO2019086890A1 (enExample)
ZA (1) ZA202002093B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
HUE066783T2 (hu) 2018-04-18 2024-09-28 Constellation Pharmaceuticals Inc Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
EP4333854A1 (en) * 2021-05-03 2024-03-13 Discuva Ltd. Antibacterial compound
EP4484609A1 (en) 2022-02-21 2025-01-01 Mitsui Chemicals, Inc. Metal member, metal-resin composite body, and method for producing metal member
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005085241A1 (ja) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (en) * 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
PL2731949T3 (pl) * 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
KR102405136B1 (ko) * 2014-05-16 2022-06-07 아트리바 테라퓨틱스 게엠베하 인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fumihiko Akutsu 외, Polymer, Vol. 39(24), pp.6093-6098 (1998)*
Hans P. L. Steenackers 외, J. Med. Chem., Vol. 54, pp.472-484 (2011)*
Pyl Theodor 외, Chemische Berichte, Vol. 94(12), pp.3217-3223 (1961)*

Also Published As

Publication number Publication date
AU2018361828A1 (en) 2020-05-28
CA3081423A1 (en) 2019-05-09
MA50504A (fr) 2020-09-09
EP3704105A1 (en) 2020-09-09
CO2020005420A2 (es) 2020-07-31
US20220372027A1 (en) 2022-11-24
CL2020001147A1 (es) 2020-08-14
ES3005164T9 (en) 2025-03-24
CL2021002263A1 (es) 2022-04-01
NZ764310A (en) 2023-04-28
PE20221006A1 (es) 2022-06-15
US11345694B2 (en) 2022-05-31
SG11202003717UA (en) 2020-05-28
PE20211390A1 (es) 2021-07-27
IL274229B1 (en) 2023-01-01
EP4606375A3 (en) 2025-11-19
GEP20237522B (en) 2023-08-10
CN111566099A (zh) 2020-08-21
MX2021010246A (es) 2021-09-21
AU2018361828B2 (en) 2023-05-18
CN111566099B (zh) 2023-06-02
JP2021501756A (ja) 2021-01-21
IL274229B2 (en) 2023-05-01
MX2020004562A (es) 2020-08-13
EP4606375A2 (en) 2025-08-27
US20210163460A1 (en) 2021-06-03
EP3704105B1 (en) 2024-10-16
UA128475C2 (uk) 2024-07-24
EP3704105B9 (en) 2025-03-05
IL274229A (en) 2020-06-30
ES3005164T3 (en) 2025-03-14
EA202091118A1 (ru) 2020-08-06
KR20200084875A (ko) 2020-07-13
GB201718285D0 (en) 2017-12-20
ZA202002093B (en) 2023-11-29
JP7348897B2 (ja) 2023-09-21
BR112020008531A2 (pt) 2020-10-20
JP2022025116A (ja) 2022-02-09
WO2019086890A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
KR102470319B1 (ko) 항균성 화합물
AU2021204116B2 (en) Colony stimulating factor-1 receptor (CSF-1R) inhibitors
KR102444482B1 (ko) 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물
KR101643435B1 (ko) 항세균성 화합물
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
JP2021523221A (ja) Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
TW201002728A (en) Heterocyclic urea derivatives and methods of use thereof
JP4819980B2 (ja) 細菌性腸管疾患の治療のための５−ヒドロキシメチル−オキサゾリジン−２−オン誘導体
WO2011151619A1 (en) Compounds for the treatment of clostridium difficile associated disease
CN111527093B (zh) 抗菌杂环化合物及其合成
EA041456B1 (ru) Антибактериальные соединения
EP3209667A1 (en) Nargenicin compounds and uses thereof as antibacterial agents
AU2017218556A1 (en) Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
BR122023019818B1 (pt) Inibidores do receptor de fator-1 de estimulação de colônia (csf-1r), composição farmacêutica e seu uso

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200529

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200604

Comment text: Request for Examination of Application

PG1501 Laying open of application
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220222

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220523

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201123

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221005

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220916

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220523

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201123

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221121

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration